Vipadenant Explained
| Image Class: | skin-invert-image |
| Routes Of Administration: | Oral |
| Class: | Adenosine A2A receptor antagonist; Antiparkinsonian agent |
| Atc Prefix: | None |
| Cas Number: | 442908-10-3 |
| Pubchem: | 21874557 |
| Iuphar Ligand: | 5612 |
| Drugbank: | DB06625 |
| Chemspiderid: | 10620930 |
| Unii: | LDR3USH1NJ |
| Kegg: | D09991 |
| Chembl: | 447664 |
| Pdb Ligand: | 9XT |
| Synonyms: | BG-14; BG14; BIIB-014; BIIB014; BIIB14; CEB-4520; V-2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; VR-2006 |
| Iupac Name: | 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine |
| C: | 16 |
| H: | 15 |
| N: | 7 |
| O: | 1 |
| Smiles: | CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N |
| Stdinchi: | 1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20) |
| Stdinchikey: | HQSBCDPYXDGTCL-UHFFFAOYSA-N |
Vipadenant (; developmental code name BIIB014 and others) is an adenosine A2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed.[1] [2] [3] [4] It is taken orally. The drug was first described in the scientific literature by 2006.[5] [6] It was under development by Vernalis, Biogen, and Juno Therapeutics. Vipadenant reached phase 2 clinical trials prior to the discontinuation of its development.
See also
Notes and References
- Web site: Vipadenant . 28 October 2024 . AdisInsight . 28 January 2026 .
- Web site: Terry M . Delving into the Latest Updates on Vipadenant with Synapse . 24 January 2026 . Synapse . 28 January 2026 .
- Pinna A . Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued . CNS Drugs . 28 . 5 . 455–474 . May 2014 . 24687255 . 10.1007/s40263-014-0161-7 .
- Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, O'Neill G . An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers . Clinical Neuropharmacology . 33 . 2 . 55–60 . 2010 . 20375654 . 10.1097/WNF.0b013e3181d137d2 .
- Lightowler, S., Knight, A. R., & Upton, R. (2006). Pharmacology of BIIB014/V2006, an A2A antagonist for the treatment of PD. Targeting Adenosine A2A Receptors in Parkinson’s Disease and Other CNS Disorders. Boston, USA. https://scholar.google.com/scholar?cluster=5861921750099200903
- Gillespie RJ, Bamford SJ, Botting R, Comer M, Denny S, Gaur S, Griffin M, Jordan AM, Knight AR, Lerpiniere J, Leonardi S, Lightowler S, McAteer S, Merrett A, Misra A, Padfield A, Reece M, Saadi M, Selwood DL, Stratton GC, Surry D, Todd R, Tong X, Ruston V, Upton R, Weiss SM . Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines . Journal of Medicinal Chemistry . 52 . 1 . 33–47 . January 2009 . 19072055 . 10.1021/jm800961g .
